Utility of Cell-Free DNA Detection in Transplant Oncology

Cancers

Rafik Mark Ghobrial¹  Jenny C. Chang²  Abdullah Esmail³  Maen Abdelrahim³  Tejaswini Reddy³ 

[1] Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA;Houston Methodist Research Institute, Houston, TX 77030, USA;Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77030, USA;

关键词: transplant oncology;    liver transplantation;    cholangiocarcinoma;    neuroendocrine tumor;    liver metastases;    hepatocellular carcinoma;   

DOI  :  10.3390/cancers14030743

来源: DOAJ

【 摘 要 】

Transplant oncology is an emerging field in cancer treatment that applies transplant medicine, surgery, and oncology to improve cancer patient survival and quality of life. A critical concept that must be addressed to ensure the successful application of transplant oncology to patient care is efficient monitoring of tumor burden pre-and post-transplant and transplant rejection. Cell-free DNA (cfDNA) detection has emerged as a vital tool in revolutionizing the management of cancer patients who undergo organ transplantation. The advances in cfDNA technology have provided options to perform a pre-transplant evaluation of minimal residual disease (MRD) and post-transplant evaluation of cancer recurrence and transplant rejection. This review aims to provide a comprehensive overview of the history and emergence of cfDNA technology, its applications to specifically monitor tumor burden at pre-and post-transplant stages, and evaluate transplant rejection.

【 授权许可】

Unknown